# Ela Borenstein

> Ela Borenstein is a Series B investor at Thrasos (Montréal) backing Health Care and Therapeutics. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Thrasos](https://shizune.co/investors/profile/thrasos)
- Location: Montréal, Canada
- Total investments: 4
- Last investment: Jun 2015
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/ela-borenstein/4/bb2/ba
- X (Twitter): http://twitter.com/elaborenstein

Ela Borenstein is a Series B investor at Thrasos in Montréal focused on Health Care and Therapeutics. Ms. Ela Borenstein serves as Managing Partner at BDC Healthcare Venture. She joined BDC Venture Capital in 2007 and has over 20 years of management, entrepreneurial and consulting experience in the biopharmaceutical industry. She also serves on the Board of Thrasos Therapeutics. Prior to joining BDC, she was Chief Operating Officer at a VC-backedbiotech and previously held the position of Vice President in clinical, regulatory affairs and product strategy for various companies, as well as Senior Vice President of Scientific Affairs for Technilab Pharma during the company’s successful IPO. Her diversified background includes senior management responsibilities in drug and medical device development as well as key involvement in product acquisition and M&A activities. She is a Kauffman Fellow Class 17, a society for leaders in venture capital. Ela is an advisor and guest lecturer with several organizations and currently serves on the Board of Directors of Alethia Biotherapeutics and Milestone Pharma where she is active in their audit and compensation committees. She holds a Bachelor of Science in Chemistry from the University of Western Ontario, a Master of Science in Pharmacology from the University of Toronto and an MBA in Bio-Industries from Université du Québec à Montréal.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 75% |
| Therapeutics | 3 | 75% |
| Biotechnology | 3 | 75% |
| Medical Device | 1 | 25% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 50% |
| Series A | 1 | 25% |
| Series D | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Milestone Pharmaceuticals | Milestone Pharmaceuticals is a drug development company developing novel small molecule therapeutics based on clinically validated mechanisms for cardiovascular diseases. Milestone's lead product is a novel and potent short-acting calcium channel antagonist for the systemic treatment of transient cardiovascular conditions such as atrialarrhythmias and angina. | $17M | Series B | Jun 15, 2015 |  |
| Thrasos | Thrasos is a bio-therapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of severe organ failure, with a principle focus on kidney disease. The Company's lead therapeutic program, THR-184, is focused on the prevention and treatment of acute kidney injury (AKI). The Company also has apreclinical development program for treating chronic kidney disease (CKD). | $21M | Series D | Mar 31, 2015 |  |
| Alethia BioTherapeutics | Alethia BioTherapeutics, Inc., a biotechnology company, engages in the discovery and development of monoclonal antibody-based therapeutics focusing on the cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and on cancer-induced bone loss. Its products include Isogranulatimide, a G2 checkpoint inhibitor, which potentiates theresponse to several DNA-damaging chemotherapeutic agents; sCLU, a heterodimeric disulphide-linked glycoprotein of 449 amino acids, the over-expression of which is observed in various malignancies, including prostate, bladder, kidney, breast, colon, and lung tumors; AB-0447, an antigen that is expressed at the surface of ovarian cancer epithelial cells in greater than eighty five percent of malignant tumors; and AB-0440, a cell-surface protease-like protein, whose expression is stimulated early in osteoclast differentiation in response to RANK ligand. The company was founded in 2002 and is based in Montreal, Canada. | $4.7M | Series B | Nov 02, 2012 |  |
| Alethia BioTherapeutics | Alethia BioTherapeutics, Inc., a biotechnology company, engages in the discovery and development of monoclonal antibody-based therapeutics focusing on the cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and on cancer-induced bone loss. Its products include Isogranulatimide, a G2 checkpoint inhibitor, which potentiates theresponse to several DNA-damaging chemotherapeutic agents; sCLU, a heterodimeric disulphide-linked glycoprotein of 449 amino acids, the over-expression of which is observed in various malignancies, including prostate, bladder, kidney, breast, colon, and lung tumors; AB-0447, an antigen that is expressed at the surface of ovarian cancer epithelial cells in greater than eighty five percent of malignant tumors; and AB-0440, a cell-surface protease-like protein, whose expression is stimulated early in osteoclast differentiation in response to RANK ligand. The company was founded in 2002 and is based in Montreal, Canada. | $9.2M | Series A | Sep 07, 2010 |  |

4 of 4 investments shown.

## Co-investors
- [AgeChem Venture Fund](https://shizune.co/investors/profile/agechem-venture-fund) — VC Fund, 2 deals together
- [GO Capital Fund](https://shizune.co/investors/profile/go-capital-fund) — VC Fund, 2 deals together
- [Pappas Ventures](https://shizune.co/investors/profile/pappas-ventures) — VC Fund, 2 deals together
- [Advanced Technology Ventures](https://shizune.co/investors/profile/advanced-technology-ventures) — VC Fund, 1 deal together
- [BDC Healthcare Venture](https://shizune.co/investors/profile/bdc-healthcare-fund) — VC Fund, 1 deal together
- [Domain Associates](https://shizune.co/investors/profile/domain-associates) — VC Fund, 1 deal together

## About Thrasos

VC Fund · Montréal, Canada

Thrasos is a bio-therapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of severe organ failure, with a principle focus on kidney disease. The Company's lead therapeutic program, THR-184, is focused on the prevention and treatment of acute kidney injury (AKI). The Company also has apreclinical development program for treating chronic kidney disease (CKD).

5 contacts available at Thrasos.

| Name | Title | Profile |
| --- | --- | --- |
| Ela Borenstein | Board Member | https://shizune.co/investors/profile/ela-borenstein |
| Andreas Orfanos | Chief Medical Officer | https://shizune.co/investors/profile/dr-andreas-orfanos |
| Jerome Rossert | Chief Scientific Officer, Chief Medical Officer | https://shizune.co/investors/profile/jerome-rossert |
| Murty Bosukonda | Co-Founder | https://shizune.co/investors/profile/murty-bosukonda |
| Philippe Bey | Senior Vice President, Research and Development | https://shizune.co/investors/profile/dr-philippe-bey |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Ela Borenstein invest in?

Ela Borenstein invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series B and Series A stage. Most of the 4 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Ela Borenstein last invest?

The most recent investment recorded for Ela Borenstein closed in Jun 2015. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co